×
About 3,665 results

ALLMedicine™ Thrombocytopenia Center

Research & Reviews  1,352 results

No apparent association between mRNA COVID-19 vaccination and venous thromboembolism.
https://doi.org/10.1016/j.blre.2022.100970
Blood Reviews; Nicholson M, Goubran H et. al.

May 17th, 2022 - By January 2022 over ten billion doses of COVID-19 vaccines had been administered worldwide. Concerns about COVID-19 vaccine-associated thrombosis arose after the characterization of a rare prothrombotic condition associated with adenoviral vector...

Cardiovascular and Hematologic Complications of COVID-19 Vaccines.
https://doi.org/10.1097/CRD.0000000000000457
Cardiology in Review; Herblum J, Frishman W

May 17th, 2022 - COVID-19 is a pro-thrombotic and cardiac-damaging disease. There are four vaccines against COVID-19 currently approved in North America, including the mRNA vaccines by Pfizer and Moderna, and the adenovirus vector vaccines by Johnson and Johnson a...

Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger...
https://doi.org/10.1111/bjh.18245
British Journal of Haematology; Petito E, Colonna E et. al.

May 17th, 2022 - To slow down the coronavirus disease 2019 (COVID-19) pandemic an unequalled vaccination campaign was initiated. Despite proven efficacy and safety, a rare but potentially fatal complication of adenoviral-vector vaccines, called vaccine-induced imm...

Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT.
https://doi.org/10.1182/blood.2021014588
Blood Kanack A, Bayas A et. al.

May 14th, 2022 - COVID-19 vaccines have been associated with a rare life-threatening thrombotic and thrombocytopenic adverse reaction, vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by high levels of platelet-activating anti-platelet facto...

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
https://doi.org/10.6004/jnccn.2022.0026
Journal of the National Comprehensive Cancer Network : JN... Griffiths EA, Roy V et. al.

May 12th, 2022 - The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced an...

see more →

Guidelines  4 results

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963252
Blood Advances; Neunert C, Terrell DR et. al.

Dec 4th, 2019 - Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. These evidence-based guidelines of t...

American Society of Hematology 2018 guidelines for management of venous thromboembolism...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258919
Blood Advances; Cuker A, Arepally GM et. al.

Nov 30th, 2018 - Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. These evidence-based ...

The American Society of Hematology 2011 evidence-based practice guideline for immune th...
https://doi.org/10.1182/blood-2010-08-302984
Blood Neunert C, Lim W et. al.

Feb 18th, 2011 - Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been...

International consensus report on the investigation and management of primary immune th...
https://doi.org/10.1182/blood-2009-06-225565
Blood Provan D, Stasi R et. al.

Oct 23rd, 2009 - Previously published guidelines for the diagnosis and management of primary immune thrombocytopenia (ITP) require updating largely due to the introduction of new classes of therapeutic agents, and a greater understanding of the disease pathophysio...

see more →

Drugs  66 results see all →

News  44 results

Physicians Assess Cardiovascular Safety of COVID-19 Vaccines
https://www.medscape.com/viewarticle/971928

Apr 11th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. This article was originally published in Portuguese on Medscape. Earlier this year, the Brazilian Society of Cardiology (SBC) released a position ...

EU Finds J&J COVID Shot Possibly Linked to Another Rare Clotting Condition
https://www.medscape.com/viewarticle/960086

Oct 4th, 2021 - (Reuters) - The European Union's drug regulator on Friday identified a possible link between rare cases of venous thromboembolism with Johnson & Johnson's COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot. The E...

Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems
https://www.medscape.com/viewarticle/955225

Jul 23rd, 2021 - NEW YORK (Reuters Health) - Organs from deceased donors who had received AstraZeneca's ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 may possibly prompt vaccine-induced thrombosis and thrombocytopenia (VITT) in recipients, according to a new study. A...

Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine
https://www.medscape.com/viewarticle/953901

Jun 28th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. What is believed to be the first case of thrombosis with thrombocytopenia after a messenger RNA COVID-19 vaccine has been reported. The case repor...

Immune Response May Explain Rare Clots After AstraZeneca Vaccine
https://www.medscape.com/viewarticle/948389

Mar 31st, 2021 - (Reuters) - Researchers may have found an explanation for the rare but serious blood clots reported among some people who received AstraZeneca's COVID-19 vaccine. They believe the phenomenon is similar to heparin-induced thrombocytopenia (HIT), in...

see more →